Henry Schein stock (US42548G1040): Global leader in dental and medical supplies

Henry Schein stands as a major player in the distribution of healthcare products, focusing on dental, medical, and animal health supplies. The company reported steady operations in its most recent quarterly results for Q1 2026, published on May 7, 2026, showing revenue of $3.2 billion, up 4% year-over-year, according to Henry Schein IR as of 05/07/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Henry Schein: core business model

Henry Schein operates as a leading distributor of healthcare products and services, primarily serving dental, medical, and veterinary practices. Founded in 1932, the company has built a vast network connecting manufacturers with frontline healthcare providers. Its business model revolves around value-added distribution, including logistics, inventory management, and technology solutions tailored for professional offices.

The dental segment forms the largest part of its operations, accounting for roughly 45% of revenue in recent periods. Henry Schein supplies equipment, consumables, and software to over one million customers globally. This segment benefits from recurring demand for disposables and steady equipment upgrades, providing revenue stability.

In the medical division, the company distributes pharmaceuticals, vaccines, and practice management tools to physician offices and pharmacies. Animal health, another key pillar, caters to veterinary clinics with similar product lines. This diversified portfolio mitigates risks from any single market segment.

Main revenue and product drivers for Henry Schein

Dental products drive the majority of Henry Schein's top line, with key categories including implants, orthodontics, and digital dentistry tools. The shift toward digital workflows has boosted demand for CAD/CAM systems and 3D printers, which the company distributes through partnerships with leading manufacturers. For Q1 2026, dental distribution revenue grew 5%, per the earnings release dated May 7, 2026, from Henry Schein IR as of 05/07/2026.

Medical supplies, such as exam room equipment and infection control products, contribute significantly, especially amid ongoing healthcare needs post-pandemic. Animal health sees growth from pet ownership trends in the US, where veterinary spending rose 7% annually according to industry data published in 2025 by IBISWorld as of 12/2025.

Technology and services, including practice management software, add high-margin recurring revenue. Henry Schein's SaaS offerings help practices streamline billing and compliance, appealing to efficiency-focused US providers.

Industry trends and competitive position

The healthcare distribution sector faces consolidation and digital transformation. Henry Schein holds a top position in dental distribution, competing with Patterson Companies and Benco Dental. Its scale enables favorable supplier terms and broad inventory, advantages for US dental practices reliant on just-in-time delivery.

Trends like value-based care and telemedicine influence medical distribution, where Henry Schein invests in integrated solutions. In animal health, rising pet humanization drives premium product sales, positioning the company well against peers like Merck Animal Health distributors.

Why Henry Schein matters for US investors

Listed on Nasdaq under ticker HSIC, Henry Schein offers US investors exposure to resilient healthcare spending. The US accounts for over 50% of its revenue, tying performance to domestic economic health and dental utilization rates, which remain stable even in downturns.

With a market cap around $10 billion as of early 2026, it provides a defensive play in healthcare distribution, less volatile than pure pharma or device makers. Its global footprint diversifies risks while US operations deliver familiarity for retail portfolios.

Conclusion

Henry Schein continues to leverage its distribution expertise across dental, medical, and animal health segments, with recent Q1 results underscoring operational resilience. Investors track its ability to navigate supply chain dynamics and capitalize on digital health trends. The company's US-centric revenue provides a stable anchor amid global uncertainties.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.